Full Press Release Details
SAN DIEGO , Sept. 27, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) scientists, together with investigators from five children's hospital across the US, have co-authored a study published today in JAMA Pediatrics reporting findings from the NICUSeq Randomized Time-Delayed Trial . Results show that use of clinical whole-genome sequencing (cWGS) outperforms usual care by two-fold both in terms of diagnostic efficacy and change of clinical management of acutely ill newborns suspected of having a genetic condition. The data support the widespread adoption and implementation of cWGS for newborns in crisis.
Children's Hospital of Philadelphia , University of Nebraska Medical Center (including the Munroe-Meyer Institute) and in partnership with Children's Hospital & Medical Center in Omaha , Children's Hospital of Orange County in conjunction with Rady Children's Institute for Genomic Medicine ( San Diego ), Washington University /St. Louis Children's Hospital and Le Bonheur Children's Hospital, the University of Tennessee Health Science Center ( Memphis, TN ) took part in study which enrolled a racially and ethnically diverse, and geographically distributed, population of acutely ill infants.
"The clear and important link between establishing a diagnosis and improved care management lends much weight to the adoption of cWGS as a first-tier diagnostic test in critically-ill newborns," said Ian Krantz MD, Professor of Pediatrics at the Children's Hospital of Philadelphia .
About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter , Facebook , LinkedIn , Instagram , and YouTube .
Investors: Brian Blanchett 1 858.291.6421 [email protected]
Media: Dr. Karen Birmingham EMEA: +44 7500 105665 US: 1 646.355.2111 [email protected]
SOURCE Illumina, Inc.